Efficacy of bevacizumab treatment for refractory brain edema
Objective This retrospective study investigated the efficacy and safety of bevacizumab treatment for refractory brain edema.Methods Bevacizumab was used for the treatment of 59 cases of brain metastatic patients with refractory brain edema in March 2009 to December 2015.The median dose of bevacizumab was 4.68mg/kg (range 2.8-6.52mg/kg).The clinical-pathological data, the efficacy and the side effects of bevacizumab were recorded.Magnetic resonance imaging (MRI) was performed before and after the use of bevacizumab.Tumor volumes and edema volumes were measured separately.Results In 59 cases, the clinical symptoms of 50 cases (84.74%) were improved the next day after the bevacizumab treatment;the edema volumes of 55 (93.22%) cases were reduced after the bevacizumab treatment.Brain MRI showed the average edema volume was significantly reduced after bevacizumab treatment (125583.43±14093.27mm3 Vs 71613.42 ±9473.42 mm3, Mann-Whitney rank test, P < 0.01), and the average edema index was significantly reduced (25.66±11.54 VS 17.87±6.87, Mann-Whitney rank test, P<0.01).One patient died of hemorrhoea in cancerous-ulcer of genyantrum.Hypertension was observed in 11 cases (18.6%) of all 59 patients.No other complication was observed in these patients.Conclusion The effective rate of bevacizumab for refractory brain edema is 84.74%.Hypertension was common adverse reaction of the bevacizumab treatment, and severe hemorrhage also should be alerted.
Brain edema Brain metastasis Bevacizumab
Meng Xiangying Zhao Rugang Shen Ge Dong Dapeng Sun Bing Ding Lijuan Wang Junliang Wu Shikai
Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
国内会议
北京
英文
422-431
2016-10-01（万方平台首次上网日期，不代表论文的发表时间）